Halozyme is transforming from a royalty-based business focused on ENHANZE technology into a broader subcutaneous drug delivery platform. The company reported a 52% increase in royalty revenue for fiscal year 2025, reaching $867.8 million, and projects 30-35% royalty growth with adjusted EBITDA between $1.125 billion and $1.205 billion for 2026. Recent acquisitions and partnerships with companies like Vertex and Takeda enhance its intellectual property and position Halozyme as a comprehensive biologic delivery solutions provider. Despite strong growth and high margins, Halozyme trades at a notable valuation discount, suggesting potential investment value.
Prestige Consumer Healthcare completed the acquisition of Australian therapeutic skin care company LaCorium Health for approximately $150 million in cash on July 1, 2026. LaCorium, known for brands like Dermal Therapy and Flexitol, generates about $4...
GuideAI Health Corp. has appointed Dr. James F. Benenati, a leading interventional radiologist, to its Advisory Board following FDA 510(k) clearance of its AI software, VascularAssist Occlusion Triage (VAOT). VAOT is designed to help radiologists pri...
Diginex Limited has agreed with Resulticks to extend the deadline for their acquisition deal to July 31, 2026, after securing firm funding intent from private investors. The company does not plan to seek public funding and expects this to be the fina...
Rogers Communications has agreed to buy the remaining 25% stake in Maple Leaf Sports & Entertainment (MLSE) from Kilmer Sports for C$4.35 billion, making Rogers the sole owner. This move aims to strengthen Rogers' position in Canadian sports and ente...
VERAXA Biotech updated on its progress in developing novel cancer therapies using its proprietary BiTAC platform, focusing on conditionally active T cell engagers and bispecific antibody-drug conjugates. The company plans to prioritize investment in ...
